This website is for UK Healthcare Professionals only

Podcast

November: Episode 5     Watch time: 20 min

Are all IL-23s the same?

The fifth episode explores how differences within the IL-23 inhibitor class may affect efficacy, safety and dosing outcomes for patients with moderate to severe psoriasis, with a focus on IL-23p19 inhibitors, including SKYRIZI® (risankizumab).

Podcast Series Host

Dr Laura Savage

Consultant Dermatologist at Leeds Centre for Dermatology, Chapel Allerton Hospital (Leeds Teaching Hospitals NHS Trust) and an Honorary Senior Lecturer at University of Leeds

Podcast Guest Speakers

Dr Shirin Zaheri

Imperial Healthcare NHS Trust and Imperial College London

 

Professor Kave Shams

University of Leeds and Leeds Centre for Dermatology

 

Podcasts:

JULY: Episode 1

Clinical trial spotlight - risankizumab and secukinumab head-to-head in plaque psoriasis

AUGUST: Episode 2

Psoriasis in the time of COVID-19: an era of virtual clinics?             

SEPTEMBER: Episode 3

Psoriasis in practice: BAD guideline updates                               

OCTOBER: Episode 4

BAD 2020: virtual congress highlights

NOVEMBER: Episode 5

Are all IL-23s the same?                    

DECEMBER: Episode 6

EADV 2020: congress highlights       

References

  1. SKYRIZI (risankizumab) Summary of Product Characteristics.

UK-RISN-210517 Date of Preparation: October 2021